Skip to main content

Propulsid Disease Interactions

There are 2 disease interactions with Propulsid (cisapride).

Major

Cisapride (applies to Propulsid) cardiac disease

Major Potential Hazard, High plausibility. Applicable conditions: Cardiovascular Disease

The use of cisapride is contraindicated in patients with cardiac disease. Serious cardiac arrhythmias, including ventricular arrhythmias and torsades de pointes associated with QT prolongation have been rarely associated with the use of cisapride, especially when taken in conjunction with other medications known to prolong the QT interval.

References

  1. (2001) "Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals
  2. Ahmad SR, Wolfe SM (1995) "Cisapride and torsades de pointes." Lancet, 345, p. 508
  3. Bran S, Murray WA, Hirsch IB, Palmer JP (1995) "Long QT syndrome during high-dose cisapride." Arch Intern Med, 155, p. 765-8
  4. Lewin MB, Bryant RM, Fenrich AL, Grifka RG (1996) "Cisapride-induced long QT interval." J Pediatr, 128, p. 279-81
  5. Wysowski DK, Bacsanyi J (1996) "Cisapride and fatal arrhythmia." N Engl J Med, 335, p. 290-1
  6. Bennett JR (1989) "How safe and acceptable is cisapride?" Scand J Gastroenterol Suppl, 165, p. 59-61
  7. Wysowski DK (1996) "Cisapride and fatal arrhythmia." N Engl J Med, 335, p. 290-1
  8. Bedu A, Lupoglazoff JM, Faure C, Denjoy I, Casasoprana A, Aujard Y (1997) "Cisapride high dosage and long QT interval." J Pediatr, 130, p. 164
  9. Grifka RG (1997) "Cisapride high dosage and long QT interval - reply." J Pediatr, 130, p. 164
  10. Hanson R, Browne G, Fasher B, Mcaskill M, Moroney P, Hawker R (1997) "Cisapride-induced prolonged QT interval: too much of a good thing!." J Pediatr, 130, p. 164-6
  11. Gunasekaran TS, DuBrow I (1997) "Cisapride-induced long QT interval: What is the role of ranitidine?" J Pediatr, 130, p. 679-80
  12. Grifka R, Lewin M (1997) "Cisapride-induced long QT interval: What is the role of ranitidine? - Reply." J Pediatr, 130, p. 680
  13. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI (1998) "Proarrhythmia associated with cisapride in children." Pediatrics, 101, p. 1053-6
  14. Gray VS (1998) "Syncopal episodes associated with cisapride and concurrent drugs." Ann Pharmacother, 32, p. 648-51
  15. Ault A (1998) "US FDA warns doctors to use cisapride as last resort only." Lancet, 352, p. 120
View all 15 references
Major

Cisapride (applies to Propulsid) GI hemorrhage/obstruction/perforation

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Gastrointestinal Obstruction, Gastrointestinal Perforation

The use of cisapride is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation. Enhanced gastrointestinal motility could be harmful in these patients.

References

  1. (2001) "Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals
  2. Quigley EMM (1994) "The clinical pharmacology of motility disorders - the perils (and pearls) of prokinesia." Gastroenterology, 106, p. 1112-4

Propulsid drug interactions

There are 362 drug interactions with Propulsid (cisapride).

Propulsid alcohol/food interactions

There is 1 alcohol/food interaction with Propulsid (cisapride).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.